TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company…
Revenues increased 7% compared to quarter from prior year and 15% from prior quarterImprovement in gross margin for quarter of…
News of the Successful Trial Comes Amid an Oversubscribed Investor Round and Preparation for Series A Financing RoundRALEIGH, NC /…
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest),…
Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024NORTHVALE, NJ /…
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…
Innovation and Sustainability Lead to Double Award Win for Qube Pro at PAC GlobalLondon, Ontario--(Newsfile Corp. - February 8, 2024)…
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host…